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ABSTRACT: Background: We aimed to assess why carers seek participation for their 
relatives in clinical trials of Alzheimer’s disease (AD) medications, and to assess 
carer impressions of the value of trial participation. Method: A retrospective 
questionnaire was sent to 31 carers of participants in clinical trials for AD conducted 
at the Mental Health Research Institute and the National Aging Research Institute 
between January 1997 and December 1999. Results: Twenty five questionnaires 
(81%) were returned, completed to an extent to permit analysis. Helping a relative 
feel better, contributing to medical science and hoping for a cure were the main 
reasons for trial participation. In general, carers found the regular consultation with 
research staff supportive and would recommend trial participation to others. 
Conclusion: A greater understanding of the motivations of carers may aid the 
recruitment and retention of participants in clinical trials. 
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BACKGROUND/INTRODUCTION 
 
Little is known about the attitudes of clinical trial participants: their opinion of 
clinical research, their expectations of trial participation, or their experience during 
trials (Karlawish et al., 2001). A search of the literature located studies of the 
impressions of two bowel treatment clinical trial groups (Madsen et al., 2000), 
outpatients (Madsen et al., 1999), and carers of dementia patients (Elad et al., 2000; 
Karlawish et al., 2001). We sought to explore these issues in regard to Alzheimer’s 
disease (AD) clinical trials.  
 
The limited evidence available suggests that participation in clinical trials is 
motivated by altruism, with carers of patients seeking enrolment to benefit other 
people (Karlawish et al., 2001) and to help future patients and science in general (Elad 
et al., 2000; Madsen et al., 2000; Terenius, 2000). Madsen et al. (1999) found that one 
third of trial participants felt a moral obligation to participate. Elad  et al. (2000) 
found that carers who enrolled in clinical trials had a higher level of hope that their 
relatives’ condition would improve compared to carers who declined to participate. In 
addition, most would have done ‘absolutely anything to improve the plight of their 
loved one’ (Karlawish et al., 2001). Carers also hoped to ease their own burden of 
care through improving the quality of life of the patient (Karlawish et al., 2001).  
 
Other reasons given for enrolling in clinical trials were trust in the doctor (Karlawish 
et al., 2001) access to new drugs (Karlawish et al., 2001; Madsen et al., 2000) the 
wish to be closely monitored (Madsen et al., 2000) family pressure and a sense of 
responsibility for the patient (Elad et al., 2000). 
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 Clinical trials for AD depend heavily on carers for information regarding cognitive 
and functional abilities of the treated patients during the course of the study. There 
has been little systematic evaluation of carers’ attitudes towards trial involvement 
upon trial completion, although Elad et al. (2000) suggested that involvement tended 
to produce a “positive outcome” for participants. They found that carers (who were 
predominantly spouses) participating in clinical trials for dementia treatments, suffer 
less “burn out” and are generally more optimistic than carers who do not consent to 
trial participation. Lacking conclusive evidence, Braunholtz et al. (2001) consider it 
apparent that clinical trials do have a favourable effect on participants. 
 
The aim of this study was to determine why the carers of people with Alzheimer’s 
disease seek the participation of their relatives in clinical trials. In addition, we sought 
to determine what their expectations of trial participation were and whether these 
expectations were met. The study also sought to assess the value of trial participation 
to carers. 
 
METHOD 
Questionnaires were posted to carers of participants in 3 industry-led clinical trials for 
AD conducted at the Mental Health Research Institute (MHRI) and the National 
Aging Research Institute (NARI), Melbourne, between January 1997 and December 
1999. This period predated the availability of cholinsterase inhibitors for AD in 
Australia. A reply paid envelope was included with the questionnaire and plain 
language statement explaining the purpose of the study. A follow up telephone call 
was made to each carer one week after postage of the questionnaire, purely to answer 
 4
any queries and to encourage return of the document. The follow-up call was made by 
a research colleague independent of the study and not known to the carers.  
 
Questions concerned basic demographic data for carers and patients, how the carer 
found out about the study, if any pressure was brought to bear from outside sources to 
participate and their hopes of trial participation. In addition, carers were asked to 
assess any physical and emotional changes both in themselves and their relative as a 
result of trial participation. There were also open-ended questions to better allow 
carers to express their opinions. 
 
The study was approved by the Behavioural and Psychiatric Research and Ethics 
Committee, North Western Health Care Network.  
 
RESULTS 
Thirty-one questionnaires were distributed, of which 27 (87%) were returned. Of 
these, 25 (81%) had been completed to an extent satisfactory to allow analysis. Two 
incomplete questionnaires were returned by other family members, with a note 
explaining the carer’s inability to complete the questionnaire (due to death or ill 
health). These could not be included in the analysis below.  
 
Demographics 
 
Carers and patients were similar across a range of demographic variables including 
age, sex, educational achievement and pre-retirement occupation. Five (20%) patients 
retired because of AD, and 9 (38%) carers retired to care for the patient. Twenty-two 
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carers ( 88%) were spouses of the patient, 2 (8%) were offspring and 1 (4%) was a 
sibling of the patient. 
 
At the time of completing the questionnaire, the mean time since diagnosis of AD was 
4.6 years (SD 2.3). The mean time the carer had been looking after the patient was 3.7 
years (SD 1.7). Eighteen (72%) patients were still living with their carer; seven (18%) 
not living with a carer were living in hostels or nursing homes.  
 
Reasons for joining and expectations of trial 
 
The reason rated by carers as most important in their decision to participate in the trial 
was a desire to help their relative feel better, or indeed, to be cured. A large majority 
also rated a wish to contribute to medical science (76%) and to improve the health of 
others (72%) as extremely important.  
 
[Insert Table 1 here] 
 
Eight (35%) carers found out about the trial from their local doctor; 6 (26%) from a 
newspaper or the radio; 4 (17%) from a friend or relative; 2 (9%) from participation in 
a previous study and 3 (13%) from other sources (Seniors’ Expo, AD Association 
Newsletter). 
 
Twenty three (95%) respondents reported that the details of the study were explained 
well to them, they were told what to expect from the trial and what was expected of 
them and their relative during the course of the study. They felt they had also been 
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given adequate information about the possible benefits of the drug under investigation. 
Twenty two (91%) responded that they had been given adequate information about 
the possible risks of the study and side effects of the drug. All respondents felt they 
had been given enough time to consider their decision prior to enrolling. 
 
Satisfaction of pre-trial expectations 
 
Upon completion of the index trial, overall impressions of participation were rated an 
extremely positive experience on a Likert scale by 16 (67%) and a moderately 
positive experience by 7 (29%) of respondents. No one reported that trial participation 
had been a negative experience. Thirteen (54%) respondents had participated with the 
patient in a clinical trial before. It could be argued that there may thus have been a 
selection bias in favour of a group of respondents who were already positively 
predisposed towards clinical trials. In fact, a negative correlation was demonstrated 
between this carer group and satisfaction with their clinical trial experience. 
 
Eight (42%) respondents felt that their expectations of study participation had been 
extremely well fulfilled; 4 (21%) moderately well fulfilled; 3 (16%) a little fulfilled, 
whilst 4 (21%) felt their expectations had not been fulfilled at all. 
 
Overall, trial involvement had little effect (negative or positive) on either carer or 
patient’s physical or emotional well-being. This is summarised in Figure 1. Twenty 
carers (87%) felt they could contact staff again if they need help in the future. Carer 
impressions at the end of the trial are presented in Table 2. 
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[ Insert Figure 1 here] 
 
[Insert Table 2 here] 
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Responses to open ended questions 
 
Carers were also asked open-ended questions regarding their experience within the 
clinical trial and a selection of their comments follows.  
 
“We went into the trial with very open minds, full of hope, even if we didn’t gain a lot 
from it, it may help somebody in the future.”  
 
“We find it hard to believe that there is no relief whatever. We just have to suffer as 
things get worse and friends disappear.” 
 
“Someone cared for us; someone understood my wife’s condition; someone 
understood what I, as carer, was experiencing. My wife has no memory of the visits, 
but at the time when we ended the trial, she was aware that it was her final visit and 
said goodbye to the staff.” 
 
“I think the visits could be shorter, as my wife got restless towards the finish of the 
visits.” 
 
“Awareness of these studies should be publicized a little more- especially to early age 
Alzheimer (sic).” 
 
“I found the trial worthwhile and helpful − especially as my husband improved. 
Pleased we took part. It was also good to talk to the staff − therapeutic.” 
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“At the end of the trial I felt a little let down as we felt very comfortable with the 
people who were attempting to help us.” 
 
“We found the staff approachable and caring. We were able to contact them by phone 
if we needed to discuss anything further after a visit. Their manner could not be 
faulted.” 
 
DISCUSSION 
The findings of this study strongly support previous work exploring reasons for 
participation in clinical trials. Improving the health of the patient and contributing to 
medical science were the dominant factors reported in the decision to enrol. This 
descriptive study of carer attitudes towards AD clinical trials revealed some important 
points that may help others involved in this type of work: that availability of follow-
up after a trial is of importance (Madsen et al. 2000) and may assist recruitment for 
future clinical trials. Our data also provide pointers for more focussed future research 
questions discussed below. 
 
Upon completion of the trial, carers were pleased to finish, although they missed the 
regular staff contact. They did not find study visits a chore. Although people felt that 
there was no change physically or emotionally as a result of participating in a clinical 
trial, the majority noted that it was a positive experience, which is consistent with the 
assumption of Braunholtz et al. (2001). Responses to open ended questions and 
impressions at the end of the trial demonstrated the value of the support of the 
research staff to the carers. 
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Carers found that regular consultation with research staff was supportive and provided 
an important therapy in itself. As a result, they would recommend trial participation to 
others. With clinical trials playing an important role in the management of people 
with dementia, it is important to determine the best practice guidelines for these trials 
to be conducted to ensure reasonable care, especially at times of screening rejection 
and at the end of the trial. In addition, this would assist recruitment for future trials if 
the reputation of the research centre were positive. 
 
Continuity of follow-up is important to carers. The availability of the clinical trial 
centre as a resource is invaluable to carers as the person with AD develops additional 
symptoms or as the disease progresses. This was demonstrated in many of the 
responses to the open-ended questions and bears out the findings of Elad et al. (2000). 
 
How do carer groups differ? Our results are drawn from participants in three industry 
led, multi-centre clinical trials conducted by specialist research institutes. Future 
research could focus on comparing attitudes of carers between centres with differing 
overall structures i.e. independent research units and those sited within a hospital 
setting. Furthermore, comparisons could be made in terms of motivation for trial 
involvement in groups caring for patients with AD and those caring for younger 
patients with terminal illnesses. 
 
In terms of structuring further research, a two part questionnaire exploring 
expectations and attitudes at baseline and again at the end of the study may lead to 
results with greater validity than those reported here.  
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Our review of the literature suggests that there are large gaps in our understanding of 
the reasons why people agree to undertake research and their attitudes to this process. 
A greater understanding of this would help study designers and investigators to ensure 
that their protocols and practice reflect the needs of their participants as well as the 
needs of science. A greater understanding of the motivations of carers may also aid 
the recruitment and retention of participants in clinical trials. 
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Table 1. Importance of factors influencing decision to participate in trial. 
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 Extremely 
important 
Moderately 
important 
Mildly 
important 
Not 
important at 
all  
Help my relative feel better 20 (95.2%) 1 (4.7%) 0 0 
Help my relative live longer 14 (66.6%) 3 (14.3%) 1 (4.7%) 3 (14.3%) 
Improve the health of others 13 (72.2%) 4 (22.2%) 1 (5.5%) 0 
Contribute to medical science 16 (76.2%) 4 (19.1%) 1 (4.7%) 0 
Family/ friends recommended it 2 (14.3%) 1 (7.1%) 2 (14.3%) 9 (64.3%) 
My doctor recommended it 6 (37.5%) 3 (18.8%) 3 (18.8%) 4 (25.0%) 
Free specialist care and tablets 4 (23.5%) 3 (17.6%) 6 (35.3%) 4 (23.5%) 
Having someone to talk to 7 (36.8%) 4 (21.1%) 4 (21.1%) 4 (21.1%) 
I was pressured by trial staff 0 0 2 (4.4%) 14 (87.5%) 
The hope the drug would cure 16 (80%) 2 (10%) 1 (5.0%) 1 (5.0%) 
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Table 2: Impressions at the end of the trial. 
 
 
 True  False 
I was pleased to finish the trial 14 (73.7%) 5 (26.3%) 
I felt my relative wasn’t any better 15 (68.2%) 7 (31.8%) 
I will miss contact with the staff 15 (75.0%) 5 (25.0%) 
The visits were becoming a chore 2 (11.1%) 16 (88.8%) 
I was sad to finish the trial 5 (26.3%) 12 (70.6%) 
I was concerned my relative was on placebo 9 (50.0%) 9 (50.0%) 
Recommendations were made for me to pursue if I wanted 13 (68.4%) 6 (31.6%%)
We were referred for ongoing care 14 (73.8%) 5 (26.3%) 
I felt I could contact the staff if I needed help in the future 20 (86.9%) 3 (13.1%) 
I felt abandoned 1 (5.5%) 17 (94.4%) 
Clinic staff organised follow up visits 10 (52.6%) 9 (47.4%) 
We received counselling 3 (16.6%) 15 (83.3%) 
 
 15
 
 
 
 
Figure 1: Emotional and physical change to patients and carers through trial 
involvement. 
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